Short answer
Corteva (CTVA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.6B (up 12.6% year over year) with net income of −$320M.
Q3 2025 key financials · XBRL
- Revenue
- $2.6B
- +12.6% YoY · −59.4% QoQ
- Net income
- −$320M
- +38.9% YoY · −124.4% QoQ
- EPS (diluted)
- −$0.46
- +38.7% YoY · −124.0% QoQ
Source: XBRL data from the Corteva (CTVA) Q3 2025 10-Q on SEC EDGAR. USD.
Corteva Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and YoY change not disclosed explicitly in provided text
- Operating cash flow improved to $(941) million for 9 months ended Sept 30, 2025 vs $(1,871) million for same period in 2024
- Cash, cash equivalents, and marketable securities $2.6B at Sept 30, 2025 vs $2.5B at Sept 30, 2024; total debt decreased to $4.4B from $5.7B YoY
- Share repurchases $270M in Q3 2025 and $500M YTD 2025 under 2024 and 2022 buyback plans; dividend increased 5.9% to $0.18 per share in Q3 2025
- Management highlights adequate liquidity, compliance with debt covenants and access to $6.3B credit lines; expects ~$ $1B total share repurchases in 2025
Risk Factors
- New regulatory risk from recent funding and staff cuts at EPA, USDA, FDA, HHS plus current federal government shutdown impacting timely approvals
- Updated material regulatory risk: reliance on Coordinated Framework for Biotechnology involving USDA, FDA, EPA authorities for seeds and pesticides
- Operational risk: potential delay in regulatory approvals directly affecting product launch timelines and market access
- Financial risk: no material liquidity or debt maturity changes disclosed compared to 2024 Annual Report
- Competitive risk carried forward: dependence on regulatory clearances for genetically modified seeds and pesticidal products to maintain market position
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corteva quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.